INPT Does Not Cause a Major Herxheimer – Worsening of Symptoms

The delivery of the INPT treatment has been well-tolerated, even by people who are sensitive to almost all medicines, making it ideal for those with MCS, MCAS, and other hypersensitivity conditions.

The way phages kill a microbe causes much less “die-off” worsening of a person’s symptoms than antibiotics and other antimicrobial products. We now know from research that a “Herx” reaction is not actually from the bacterial guts (endotoxins) spilling into the body as the bacteria are killed as with antibiotics. A Herx reaction is due to the proinflammatory cytokines released by the body’s immune cells that engulfed the dying bacteria. With phage killing of the bacteria the bacteria explodes where it sits and only the debris is cleaned up by the immune cells. The debris does not cause much of a proinflammatory cytokine release and therefore the best treatment outcome is possible, faster and complete annihilation of the target microbe, with less worsening of the patient’s symptoms.

Ongoing Development of INPT at the Biologix Center

INPT was developed by Phagen Corp. and is being used at the Biologix Center for Optimum Health, as a part of an IRB study, to go beyond Borrelia and target any microbial issue, including all of the co-infections associated with Lyme disease, as well as Candida sp., mold, and parasite infections, however at this time the only lab test for detecting bacteria-specific phages is for Borrelia strains.

The future of INPT includes intravenous and injectable, in addition to the oral medication, through doctors only. It is not projected to sell directly to the public at this time.

If you would like to participate in our one to two week INPT programs please contact us at www.biologixcenter.com/get-treatment/Financial assistance is available for those with chronic illness of any type, who desire treatment at Biologix Center and are struggling financially.

A more detailed report of these findings are presently being edited for publication in peer-reviewed article submission.

Bartonella Research Collaboration

The Biologix Center is collaborating with researchers who are working to develop phage lab tests for Bartonella and other types of microbes. The Phelix Bartonella-Phage Test is hoped to be offered before the end of 2020. If you have been diagnosed with Bartonella and would like to contribute a blood sample for the development of this new test, please let us know. Offer available only to patients of the Biologix Center who have been pre-qualified by our testing.

 

To learn more about Bacteriophages and INPT please click on the hyperlink.

*INPT is a patent-pending innovation developed by Phagen Corp, and is being researched at the Biologix Center for Optimum Health, in Franklin, Tennessee. A patient-funded, Retrospective Registry IRB is in place to publish peer-reviewed articles as this clinical work progresses. Approximately 98% of funds go to support the ongoing research.

There are no financial or academic conflicts to be reported between Biologix Center for Optimum Health and RED Laboratories.